Proteasome Function in Antigen Presentation: Immunoproteasome Complexes, Peptide Production, and Interactions with Viral Proteins
Overview
Authors
Affiliations
Proteasomes are the major nonlysosomal protein degradation machinery in eukaryotic cells and they are largely responsible for the processing of antigens for presentation by the MHC class I pathway. This review concentrates on recent developments in the area of antigen processing. Specialized proteasomes called immunoproteasomes and an 11S regulator of proteasomes (PA28) are induced by interferon-gamma, but it is not entirely clear why changes in proteasome structure are beneficial for antigen presentation. Different proteasome complexes have distinct subcellular distributions and subtle differences in cleavage specificity. Thus it is likely that the efficiency of production of MHC class I binding peptides varies in different locations. Immunoproteasome subunits are enriched at the ER where TAP transports peptides for association with newly synthesized MHC class I molecules. There is recent evidence to suggest that antigen presentation from viral expression vectors, or from peptides that are either delivered by bacterial toxins or derived from signal peptides, require proteasome activity for generation of the correct C-terminus of the epitope. The correct N-terminus may be generated by recently identified ER associated aminopeptidases. A number of viral protein interactions with proteasome subunits have been reported and such interactions may interfere with host anti-viral defenses and also contribute to mechanisms of cell transformation.
Hameed M, Daamen A, Hossain M, Coutermarsh-Ott S, Lipsky P, Weger-Lucarelli J bioRxiv. 2024; .
PMID: 39416014 PMC: 11482886. DOI: 10.1101/2024.10.10.617696.
Rana P, Ignatz-Hoover J, Driscoll J Cancers (Basel). 2023; 15(23).
PMID: 38067336 PMC: 10705104. DOI: 10.3390/cancers15235632.
Isolation of Proteasome-Trapped Peptides (PTPs) for Degradome Analysis.
Sahu I, Sahoo M, Kleifeld O, Glickman M Methods Mol Biol. 2022; 2602:229-241.
PMID: 36446979 DOI: 10.1007/978-1-0716-2859-1_17.
Liu J, Mi J, Liu S, Chen H, Jiang L FEBS Open Bio. 2022; 12(11):2025-2041.
PMID: 36062301 PMC: 9623531. DOI: 10.1002/2211-5463.13479.
Galectin-9 and PSMB8 overexpression predict unfavorable prognosis in patients with AML.
Zhang Y, Xue S, Hao Q, Liu F, Huang W, Wang J J Cancer. 2021; 12(14):4257-4263.
PMID: 34093826 PMC: 8176406. DOI: 10.7150/jca.53686.